Showing 1871-1880 of 5063 results for "".
- Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitishttps://practicaldermatology.com/news/realm-therapeutics-submits-investigational-new-drug-application-for-pr022-for-atopic-dermatitis/2458305/Realm Therapeutics plc submitted its first investigational new drug (IND) application to the FDA for PR022 as a novel treatment for atopic dermatitis (AD). Pending acceptance, the IND will enable Realm to initiate a Phase 2a proof-of-concept trial for patients with atopic dermatitis.
- Sun Pharma Introduces Leave Acne Behind Patient Initiativehttps://practicaldermatology.com/news/sun-pharma-introduces-leave-acne-behind-patient-initiative/2458310/Sun Pharma introudced a new initiative— “Leave Acne Behind™" — to educate patients and create awareness of severe recalcitrant nodular acne (SRNA). Sun Pharma reports that out of all of the prescription- treated acne cases today, 20 percent represent severe acne condi
- Specialty Pharma Industry Vet Charles Gregory Vontz Joins BioPharmX Board of Directorshttps://practicaldermatology.com/news/specialty-pharma-industry-vet-charles-gregory-vontz-joins-biopharmx-board-of-directors/2458311/Charles "Greg" Vontz is joining rhe Board of Directors of BioPharmX Corporation as an independent director, effective as of Jan. 17. Vontz's appointment expands the board to four directors, three of whom are independent.
- Radiesse Hits Double Digitshttps://practicaldermatology.com/news/radiesse-hits-double-digits/2458312/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was released to the publi
- Umbrellas Plus Sunscreen Needed to Stave Off Sunburnshttps://practicaldermatology.com/news/umbrellas-plus-sunscreen-needed-to-stave-off-sunburns/2458317/When it comes to preventing sunburns, neither beach umbrella or SPF 100 sunscreen are enough on their own, according to a new study in JAMA Dermatology that suggests both are needed for sufficient sun prote
- NeoStrata Debuts Exuviance AGE REVERSE Hand Rejuvenatorhttps://practicaldermatology.com/news/neostrata-debuts-exuviance-age-reverse-hand-rejuvenator/2458321/NeoStrata Company, Inc. is rolling out Exuviance AGE REVERSE Hand Rejuvenator, an intensive two-step peel. This 10% Citric Acid Peel gently exfoliates rough patches, uncovering smooth skin and preparing hands for the Exuviance AGE REVERSE Hand R
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- La Roche-Posay Debuts New Prebiotic Skincare Linehttps://practicaldermatology.com/news/la-roche-posay-debuts-new-prebiotic-skincare-line/2458323/La Roche-Posay is rolling out a new prebiotic Skincare Line. TOLERIANE Double Repair Moisturizer comes in a full line of products, including an SPF version and two complementary cleansers. The skin's microbiome is comprised of more than 100 b
- Scarless Wound Healing Breakthrough: Researchers Turn Myofibroblasts in Wounds into Adipocyteshttps://practicaldermatology.com/news/scarless-wound-healing-breakthrough-researchers-turn-myofibroblasts-in-wounds-into-adipocytes/2458326/Scientists can now transform myofibroblasts found in wounds into adipocytes, paving the way toward scarless healing. Researchers began this work at the Perelman School of Medicine at the University of Pennsylvania, which led to a large-scale, multi-year study in connection with the P
- Enrollment Complete in BioPharmX's Phase 2b Study of Topical Minocycline Gel for Acnehttps://practicaldermatology.com/news/enrollment-complete-in-biopharmx-phase-2b-study-of-topical-minocycline-gel/2458331/BioPharmX Corporation completed enrollment in the OPAL (tOPicAL Minocycline Gel) study, a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, dou